Citations

Clear

171 citation(s) found for "Moss, M".

Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction
Murtagh, Gillian , Laffin, Luke J. , Beshai, John F., Maffessanti, Francesco , Bonham, Catherine A. , Yu, Zoe, Addetia, Karima , Mor‐Avi, Victor , Sweiss, Nadera , Lang, Roberto M. , Patel, Amit R. , Patel, Amit V, Mor-Avi, Victor, Moss, Joshua D, Hogarth, D. Kyle , Sweiss, Nadera J, Patel, Amit , Moss, Joshua D.

Mayo Clinic

Circulation: Cardiovascular Imaging | January 14, 2016 | Volume: 9 | Issue: 1 | Pages: No page available

10.1161/circimaging.115.003738 | PMID 26763280 Get It

Background— Cardiac sarcoidosis is associated with an increased risk of heart failure and sudden death, but its risk in patients with preserved left ventricular ejection fraction is unknown. Using cardiovascular magnetic resonance in patients with extracardiac sarcoidosis and preserved left ventricular ejection fraction, we sought to (1) determine the prevalence of cardiac sarcoidosis or associated myocardial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their risk of death/ventricular tachycardia (VT), and (3) identify imaging-based covariates that predict who is at greatest risk of death/VT. Methods and Results— Parameters of left and right ventricular function and LGE burden were measured in 205 patients with left ventricular ejection fraction >50% and extracardiac sarcoidosis who underwent cardiovascular magnetic resonance for LGE evaluation. The association between covariates and death/VT in the entire group and within the LGE+ group was determined using Cox proportional hazard models and time-dependent receiver–operator curves analysis. Forty-one of 205 patients (20%) had LGE; 12 of 205 (6%) died or had VT during follow-up; of these, 10 (83%) were in the LGE+ group. In the LGE+ group (1) the rate of death/VT per year was >20× higher than LGE− (4.9 versus 0.2%, P <0.01); (2) death/VT were associated with a greater burden of LGE (14±11 versus 5±5%, P <0.01) and right ventricular dysfunction (right ventricular EF 45±12 versus 53±28%, P =0.04). LGE burden was the best predictor of death/VT (area under the receiver-operating characteristics curve, 0.80); for every 1% increase of LGE burden, the hazard of death/VT increased by 8%. Conclusions— Sarcoidosis patients with LGE are at significant risk for death/VT, even with preserved left ventricular ejection fraction. Increased LGE burden and right ventricular dysfunction can identify LGE+ patients at highest risk of death/VT.
Adverse Event Rates Associated with Transforaminal and Interlaminar Epidural Steroid Injections: A Multi-Institutional Study
El-Yahchouchi, Christine, Plastaras, Christopher T. , Maus, Timothy P. , McCormick, Zachary L. , Geske, Jennifer R. , Smuck, Matthew , Pingree, Matthew J. , Kennedy, David J. , Carr, Carrie M. , Geske, Jennifer

Mayo Clinic

Pain Medicine | November 23, 2015 | Volume: 17 | Issue: 2 | Pages: 239-247

10.1111/pme.12896 | PMID 26593277 Get It

Abstract Background. Transforaminal epidural steroid injections (TFESI) have demonstrated efficacy and effectiveness in treatment of radicular pain. Despite little evidence of efficacy/effectiveness, interlaminar epidural steroid injections (ILESI) are advocated by some as primary therapy for radicular pain due to purported greater safety. Objective. To assess immediate and delayed adverse event rates of TFESI and ILESI injections at three academic medical centers utilizing International Spine Intervention Society practice guidelines. Methods. Quality assurance databases from a Radiology and two physical medicine and rehabilitation (PM&R) practices were interrogated. Medical records were reviewed, verifying immediate and delayed adverse events. Results. There were no immediate major adverse events of neurologic injury or hemorrhage in 16,638 consecutive procedures in all spine segments (14,956 TFESI; 1,682 ILESI). Vasovagal reactions occurred in 1.2% of procedures, more frequently ( P = 0.004) in TFESI (1.3%) than ILESI (0.5%). Dural punctures occurred in 0.06% of procedures, more commonly after ILESI (0.2% vs 0.04%, P = 0.006). Delayed follow up on PM&R patients (92.5% and 78.5, next business day) and radiology patients (63.1%, 2 weeks) identified no major adverse events of neurologic injury, hemorrhage, or infection. There were no significant differences in delayed minor adverse event rates. Central steroid response (sleeplessness, flushing, nonpositional headache) was seen in 2.6% of both TFESI and ILESI patients. 2.1% of TFESI and 1.8% of ILESI patients reported increased pain. No long-term sequelae were seen from any immediate or delayed minor adverse event. Conclusions. Both transforaminal and ILESI are safely performed with low immediate and delayed adverse event rates when informed by evidence-based procedural guidelines. By demonstrating comparable safety, this study suggests that the choice between ILESI and TFESIs can be based on documented efficacy and effectiveness and not driven by safety concerns.
Glucose homeostasis after simultaneous pancreas and kidney transplantation: a comparison of subjects with C‐peptide‐positive non‐type 1 diabetes mellitus and type 1 diabetes mellitus
Chakkera, Harini A. , Kudva, Yogish C. , Chang, Yu‐Hui H., Heilman, Raymond L. , Singer, Andrew L., Mathur, Amit K. , Hewitt, Winston R. , Khamash, Hasan , Huskey, Janna L. , Katariya, Nitin , Moss, Adyr A. , Behmen, Senaida, Reddy, Kunam S. , Khamash, Hasan A, Katariya, Nitin N , Chakkera, Harini A

Mayo Clinic

Clinical Transplantation | October 20, 2015 | Volume: 30 | Issue: 1 | Pages: 52-59

10.1111/ctr.12658 | PMID 26485408 Get It

AbstractBackgroundWhile simultaneous pancreas kidney transplant (SPKTx) is a therapeutic option for patients with type 1 diabetes (T1DM) and renal failure, few centers offer SPKTx to “select” non‐T1DM patients. To address concerns that existing insulin resistance may limit the benefits of the pancreas allograft among non‐T1DM, we compared several indices of glucose homeostasis, in “select” non‐T1DM and T1DM patients who received SPKTx.MethodsCriteria for “select” non‐T1DM included the following: positive C‐peptide, BMI <30 kg/m2, treatment with oral agents before insulin initiation, and insulin at <1 unit/kg/d. We compared several indices of glucose homeostasis within 1 yr post‐SPKTx among seven “select” patients with non‐T1DM and nine patients with T1DM with similar age, BMI, and immunosuppression. Measurements of insulin resistance included the following: homeostatic model, insulin sensitivity index, and insulin–glucose ratio; insulin secretion measures included the following: corrected insulin response.ResultsNon‐T1DM had similar pre‐transplant metabolic (fasting glucose, HbA1c, blood pressure, and lipid) parameters to the T1DM cohort. There were no significant differences in the various measures of insulin resistance and secretion between T1DM and “select” non‐T1DM patients.ConclusionOur results suggest SPKTx should be considered in the therapeutic armamentarium among carefully select non‐T1DM with features of minimal insulin resistance; however, a larger cohort with longer follow‐up is needed to confirm our results.
Delayed allograft inflammation following alemtuzumab induction for kidney transplantation
Heilman, Raymond L. , Khamash, Hasan , Chakkera, Harini A. , Moss, Adyr A. , Reddy, Kunam S. , Smith, Maxwell L. , Chakkera, Harini A

Mayo Clinic

Clinical Transplantation | August 8, 2013 | Volume: 27 | Issue: 5 | Pages: 772-780

10.1111/ctr.12201 | PMID 23924146 Get It

AbstractBackgroundIn a recent clinical trial in kidney transplant recipients, induction with alemtuzumab and rabbit‐antithymocyte globulin (r‐ATG) was equally effective in preventing rejection during the first post‐transplant year; however, this study did not include protocol biopsies.MethodsThe aim of this study was to analyze the impact of alemtuzumab induction on rejection and subclinical inflammation during the first post‐transplant year compared with a historic control group receiving induction with r‐ATG. All patients received tacrolimus and mycophenolate mofetil (MMF).ResultsThere were 361 in the alemtuzumab group and 478 in the r‐ATG groups. Rejection (excluding Banff borderline), during the first year, occurred in 14% of the alemtuzumab group and 9% of the r‐ATG group (p = 0.03). Estimated glomerular filtration rate (GFR) (chronic kidney disease (CKD)‐EPI formula) at one yr and graft survival at three yr were similar. On the protocol biopsies, interstitial inflammation (Banff i scores) and tubulitis (Banff t scores) were more likely in the r‐ATG group at one month, but at four and 12 months, both inflammation and tubulitis were more likely in the alemtuzumab group.ConclusionsWe conclude that alemtuzumab induction is associated with delayed inflammation at four and 12 months, but this inflammation did not appear to negatively impact the GFR or graft survival.
Reply: Characterization of Lymphangioleiomyomatosis as a Neoplastic Disease
McCormack, Francis X. , Colby, Thomas V. , Moss, Joel, Мirrakhimov, Erkin М , Travis, William D. , Henske, Elizabeth P. , McCormack, Francis X

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 1, 2013 | Volume: 188 | Issue: 3 | Pages: 398-399

10.1164/rccm.201301-0199le | PMID 23905529 Get It

Use of Compliance Measures in an Analysis of the Effect of Diltiazem on Mortality and Reinfarction After Myocardial Infarction
Oakes, David , Moss, A.J., Fleiss, Joseph L., Bigger, J. Thomas, Therneau, TM, Eberly, Shirley , Manatunga, Amita K. , Carleen, Eric, Benhorin, Jesaia, Post-Infa, The Multicenter Diltiazem, McDermott, Michael P. , McDermott, Michael

Mayo Clinic

Journal of the American Statistical Association | December 20, 2012 | Volume: 88 | Issue: 421 | Pages: 44-49

10.1080/01621459.1993.10594287 Get It

Lymphangioleiomyomatosis: Calling It What It Is: A Low-Grade, Destructive, Metastasizing Neoplasm
McCormack, Francis X. , Colby, Thomas V. , Moss, Joel , Travis, William D. , Henske, Elizabeth P. , McCormack, Francis X

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 17, 2012 | Volume: 186 | Issue: 12 | Pages: 1210-1212

10.1164/rccm.201205-0848oe | PMID 23250499 Get It

High-Risk Long QT Syndrome Mutations in the Kv7.1 (KCNQ1) Pore Disrupt the Molecular Basis for Rapid K+ Permeation
Burgess, Don E. , Bartos, Daniel C. , Reloj, Allison R., Campbell, Kenneth S. , Johnson, Jonathan N. , Tester, David J. , Ackerman, Michael J. , Fressart, Véronique , Guicheney, Pascale , Moss, Arthur J. , Ohno, Seiko , Horie, Minoru , Delisle, Brian P. , Denjoy, Isabelle , Ohno, Seiko , Horie, Minoru

Mayo Clinic

Biochemistry | October 23, 2012 | Volume: 51 | Issue: 45 | Pages: 9076-9085

10.1021/bi3009449 | PMID 23092362 Get It

CT Grading of Lung Disease in Lymphangioleiomyomatosis
Yao, Jianhua , Taveira‐DaSilva, Angelo M., Colby, Thomas V. , Moss, Joel

Mayo Clinic

American Journal of Roentgenology | September 20, 2012 | Volume: 199 | Issue: 4 | Pages: 787-793

10.2214/ajr.11.7888 | PMID 22997369 Get It

Abstract 3276: A novel in vivo xenograft mouse model of human high-grade serous ovarian cancer, with clinical, molecular and functional annotation relevant for pre-clinical analysis
Topp, Monique, Hartley, Lynne, Cook, Michele , Etemadmoghadam, Dariush , Galleta, Laura, Moss, Phillip, Pyman, Jan, McNally, Orla , Kaufmann, Scott H. , Kerr, Jeff B., AOCS, Australian Ovarian Cancer Study, Haluska, Paul , Swisher, Elizabeth M. , Wakefield, Matthew J. , Bowtell, David D.L. , Scott, Clare L. , Kaufmann, Scott H

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 3276-3276

10.1158/1538-7445.am2012-3276 Get It

Abstract Background: The five year survival rate for women with ovarian cancer (OC) is less than 40%. Crucial to improving the outcomes for ovarian cancer patients is the development of accurate pre-clinical models of human epithelial OC, which can be used to unravel the mechanisms underlying its evolution and behaviour. Methods: We have generated a novel xenograft model of human high-grade serous OC (HG-SOC) in order to enable preclinical molecular and drug response assessment of individual HG-SOC: this includes a comparison of standard OC xeno-transplantion approaches (intra-peritoneal, subcutaneous and sub renal capsular), with the novel use of the rodent ovarian bursa, the orthotopic site. Utilising the rodent bursa may better replicate the relevant microenvironment and increase the success of EOC xeno-transplantion. Other aspects designed to optimize the model include the use of NOD-SCID-IL-2rg recipient mice, systemic estrogen supplementation and transplantation of fresh human HG-SOC fragments which have had no prior in vitro culture. Histological, functional and molecular analysis of the novel xenograft cohort (at baseline and following xenotransplantation) includes histological review; documentation of in vitro Homologous Recombination (HR) DNA repair and drug response capabilities (using novel α-irradiation and explant drug assays); classification according to molecular subtype (Tothill classfier); documentation of NHEJ pathway status, BRCA1/2 status and other DNA repair gene status. In vivo drug treatment studies are being performed, with the choice of treatment targeted to the specific molecular characteristics of the HG-SOC in question. Results: Fourteen consecutive chemotherapy naive potentially HG-SOC samples have been collected. Corresponding clinical data has been collected. Data concerning DNA repair capability and response to DNA damaging agents will be presented, including IHC for markers of DNA damage (γH2AX), DNA repair (RAD51) and apoptosis (capsase 3 cleavage). HG-SOC in this cohort have been classified according to Tothilll (Tothill et al 2008). Eight appropriate HG-SOC have been transplanted and 5 of the first 6 have successfully xenografted, with phenotyping of xenografts underway. In vivo analysis of response to cisplatin treatment and other relevant therapeutics will be presented. Conclusions: A novel xenograft model has been developed of human HG-SOC, which includes comparative characterization of important prognostic features both in the baseline panel of fresh human HG-SOC and in subsequent xenografts. This clinically, functionally and molecularly annotated consecutive xenograft cohort of HG-SOC will provide outstanding utility for the development of improved therapeutic approaches. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3276. doi:1538-7445.AM2012-3276